Imunon regains Nasdaq minimum bid price compliance, deficiency resolved

Imunon, Inc.

Nasdaq notified Imunon on April 10, 2024, that compliance with Listing Rule 5550(a)(2) was regained after 10 consecutive trading days with bid price over $1.00.
The deficiency notice from December 26, 2023, is now fully resolved; stock maintains listing on Nasdaq Capital Market under symbol IMNN.
Executive Chairman notes topline results from OVATION 2 Study for IMNN-001 in advanced ovarian cancer expected mid-2024.
Company plans to begin Phase 1 study of COVID-19 booster vaccine (IMNN-101) in Q2 2024 after FDA IND clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.